Jiangsu GDK Biotechnology Co Ltd banner
J

Jiangsu GDK Biotechnology Co Ltd
SSE:688670

Watchlist Manager
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Watchlist
Price: 18.66 CNY -1.37% Market Closed
Market Cap: ¥2.3B

Relative Value

The Relative Value of one Jiangsu GDK Biotechnology Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 18.66 CNY, Jiangsu GDK Biotechnology Co Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Jiangsu GDK Biotechnology Co Ltd Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Jiangsu GDK Biotechnology Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
2.3B CNY 19.7 -18.2 -13.2 -13.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
388.4B USD 6.4 92.8 15.3 21.2
US
Amgen Inc
NASDAQ:AMGN
197.4B USD 5.4 25.6 14.7 14.7
US
Gilead Sciences Inc
NASDAQ:GILD
179.9B USD 6.1 21.2 13.2 16.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.2B USD 9.9 30.2 22.7 23.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD 5.5 17.5 12.9 14.8
AU
CSL Ltd
ASX:CSL
68B AUD 3.1 34.5 11.4 14.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
37.8B EUR 10.6 34 36.8 37.6
P/S Multiple
Revenue Growth P/S to Growth
CN
J
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Average P/S: 3 063 004.6
19.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.4
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.1
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.5
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.6
27%
0.4
P/E Multiple
Earnings Growth PEG
CN
J
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Average P/E: 36.5
Negative Multiple: -18.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
92.8
97%
1
US
Amgen Inc
NASDAQ:AMGN
25.6
20%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
21.2
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
16%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
13%
1.3
AU
CSL Ltd
ASX:CSL
34.5
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
34
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
J
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Average EV/EBITDA: 18.2
Negative Multiple: -13.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
14.7
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
9%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
18%
0.7
AU
CSL Ltd
ASX:CSL
11.4
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
36.8
50%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
J
Jiangsu GDK Biotechnology Co Ltd
SSE:688670
Average EV/EBIT: 20.4
Negative Multiple: -13.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.2
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.7
3%
4.9
US
Gilead Sciences Inc
NASDAQ:GILD
16.3
13%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.8
23%
0.6
AU
CSL Ltd
ASX:CSL
14.3
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
37.6
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett